Wall Street Expecting Delays to Antitrust Clearance for Cephalon/Teva Deal (CEPH) (TEVA)
Get Alerts CEPH Hot Sheet
Join SI Premium – FREE
DealReporter is saying the potential deal between Cephalon (Nasdaq: CEPH) and Teva (Nasdaq: TEVA) may take longer-than-expected to get antitrust clearance as the transaction would include a number of reverse settlements.
Specifically, DealReporter's sources say Cephalon and Teva have been "singled out" due to their "pay-for-delay" practices.
Specifically, DealReporter's sources say Cephalon and Teva have been "singled out" due to their "pay-for-delay" practices.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon (AMZN) Invests Additional $2.75B in Anthropic - Bloomberg
- Liberty Media in Exclusive Talks to Buy Dorna Sports For EUR 4B - FT
- Masimo Corp. (MASI) May Look at Joint Venture for Consumer Split, CEO Says - WSJ
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!